Stuttgart - Delayed Quote EUR

Cassava Sciences Inc (PX91.SG)

20.24

+0.54

(+2.74%)

As of 8:02 AM GMT+2. Market Open.

Redemption Date Announced for Warrants

Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of

GlobeNewswire 10 days ago

SAVA

SAVAW
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th

GlobeNewswire last month

SAVA

SAVAW
Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock

Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...

Simply Wall St. last month

SAVAW
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024. Presentation details Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 T

GlobeNewswire last month

SAVA

SAVAW
Cassava Sciences Inc (SAVA) Reports Full-Year 2023 Financial Results

Key Financials and Corporate Updates Highlighted

GuruFocus.com last month

SAVAW
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies.Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024.Internal Investigation by Outside Counsel Has Found No Evidence to Substantiate Allegations of Research Misconduct by the Company. AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:

GlobeNewswire last month

SAVA

SAVAW
Exit Now! 3 Biotech Stocks to Sell in February 2024

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas

InvestorPlace 2 months ago

NVAX

INCY

SAVAW
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study

GlobeNewswire 2 months ago

SAVA

SAVAW
Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst retail investors who own 59% of the shares, institutions hold 31%

Key Insights Cassava Sciences' significant retail investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 2 months ago

SAVAW
Is There Any Hope for Cassava Sciences Stock?

Battered by controversy, this company will need to show real results to prosper.

Motley Fool 2 months ago

SAVAW
3 Biotech Stocks to Sell in January Before They Crash and Burn

The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies’ performance relies heavily on drug approvals. A major drug approval has the potential to multiply stock price several times, while a failure to reach approval may cause an immediate, sharp decline. For the following reasons, it is important to choose biotech investments carefully. Below are th

InvestorPlace 2 months ago

SAVAW

HALO

MNKD
Cassava Sciences Stock Continues Showing Rising Relative Strength

On Tuesday, Cassava Sciences reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 92, up from 87 the previous trading day. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. Cassava Sciences stock has recently cleared several key moving averages.

Investor's Business Daily 3 months ago

SAVAW
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW”Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the “Warrants”) to its shareholders. The War

GlobeNewswire 3 months ago

SAVA

SAVAW
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Motley Fool 3 months ago

PLUG

SAVA

LXRX
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 4 months ago

SAVA
Why Cassava Sciences Stock Zoomed 21% Higher This Week

The company has chosen an offbeat way to keep its investors sweet.

Motley Fool 4 months ago

SAVA
Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group.

Investor's Business Daily 4 months ago

SAVA
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warra

GlobeNewswire 4 months ago

SAVA
Why Cassava Sciences Stock Soared Today

Ambitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher. Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors. Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management.

Motley Fool 4 months ago

SAVA
Cassava Sciences Appoints Three New Members to its Board of Directors

Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i

GlobeNewswire 4 months ago

SAVA

Performance Overview

Return	PX91.SG	S&P 500
YTD	+0.20%	+5.84%
1-Year	+2.85%	+23.99%
3-Year	-32.44%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cassava Sciences Inc (PX91.SG)

Redemption Date Announced for Warrants

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Cassava Sciences Inc (SAVA) Reports Full-Year 2023 Financial Results

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Exit Now! 3 Biotech Stocks to Sell in February 2024

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst retail investors who own 59% of the shares, institutions hold 31%

Is There Any Hope for Cassava Sciences Stock?

3 Biotech Stocks to Sell in January Before They Crash and Burn

Cassava Sciences Stock Continues Showing Rising Relative Strength

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Why Cassava Sciences Stock Zoomed 21% Higher This Week

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Why Cassava Sciences Stock Soared Today

Cassava Sciences Appoints Three New Members to its Board of Directors

Performance Overview